scispace - formally typeset
A

Arnon Nagler

Researcher at Sheba Medical Center

Publications -  1435
Citations -  51740

Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.

Papers
More filters
Journal ArticleDOI

Gene expression during chemically induced liver fibrosis: Effect of halofuginone on TGF-β signaling

TL;DR: The role of TGF-β signaling in liver fibrosis and especially its potential for pharmacological intervention is highlighted and halofuginone, which has demonstrated efficacy and tolerance in animals and humans, could become an effective and novel therapy for Liver fibrosis.
Journal ArticleDOI

Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.

TL;DR: Halofuginone could be used as an important means of understanding the role of collagen inAdhesion formation and might become a novel and promising antifibrotic agent for preventing adhesion formation after pelvic surgery.
Journal ArticleDOI

Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors.

TL;DR: A highly significant correlation of HPSE gene SNPs rs4693608 and rs4364254 and their combination with the risk of developing acute and extensive chronic GVHD is indicated and a possible mechanism for the aggressive behavior of T lymphocytes leading to GV HD is suggested.